Dongyao Pharmaceutical's net loss for the fiscal year 2025 is 100 million RMB
Dongyao Pharmaceutical-B (01875.HK) announced its unaudited financial data for the fiscal year 2025, with operating revenue of 748 million RMB, a year-on-year decrease of 31.9%. It recorded a net loss of 100 million RMB, compared to a net profit of 34.76 million RMB in the previous year, turning from profit to loss
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments